Intel stock spikes after report of possible US government stake
On Thursday, H.C. Wainwright reiterated a Buy rating on VYNE Therapeutics (NASDAQ:VYNE), maintaining a price target of $5.75. Currently trading at $2.52, the stock shows potential upside according to analyst consensus, with targets ranging from $5.00 to $8.00. InvestingPro analysis suggests the stock is currently undervalued, with additional metrics available to subscribers. The firm’s analyst highlighted VYNE’s recent progress in a Phase 1b clinical trial for its drug candidate VYN202, designed to treat moderate-to-severe plaque psoriasis. VYNE announced the dosing of the first patient in the trial on February 19, following positive topline data from the Multiple Ascending Dose (MAD) portion of the Phase 1a study in healthy volunteers. The Phase 1a results indicated that VYN202 was safe and effectively inhibited the production of inflammatory biomarkers linked to plaque psoriasis.
The ongoing Phase 1b trial aims to enroll up to 80 patients to test three different daily doses of VYN202 against a placebo. The primary goal of the trial is to evaluate the safety of the drug, with additional endpoints including changes from baseline in the Psoriasis Area and Severity Index (PASI) and the achievement of PASI 75. Secondary endpoints cover further PASI measures, Scalp Physician’s Global Assessment (sPGA), Dermatology Life Quality Index (DLQI), and a detailed biomarker analysis.
The analyst expressed confidence in VYN202’s potential to create clinical and commercial value for VYNE Therapeutics. The selection of plaque psoriasis as the initial indication for the drug was commended as a strategic move. The company’s strong financial position is reflected in its healthy current ratio of 5.81, with more cash than debt on its balance sheet. InvestingPro data reveals the company has maintained solid liquidity, with liquid assets exceeding short-term obligations. VYNE is expected to provide further updates on the program, including the potential initiation of a parallel Phase 1b trial for rheumatoid arthritis or other inflammatory diseases.
Topline results from the 12-week placebo-controlled treatment period of the Phase 1b trial are anticipated by the end of 2025. With the next earnings report due on March 5, 2025, investors will be closely watching for updates. The analyst’s maintained Buy rating and price target reflect a positive outlook on the stock’s potential, bolstered by the company’s recent advancements in its clinical program. For deeper insights into VYNE’s financial health and growth prospects, including 7 additional key ProTips, visit InvestingPro.
In other recent news, VYNE Therapeutics has initiated a Phase 1b trial for their drug candidate VYN202, aimed at treating moderate-to-severe plaque psoriasis. The trial will evaluate the safety, pharmacokinetics, and preliminary efficacy of VYN202 over a 12-week period, involving approximately 80 subjects. This development follows the favorable safety profile seen in previous trials, with results anticipated by the end of 2025. Additionally, H.C. Wainwright has maintained a Buy rating on VYNE Therapeutics, citing the progress in their clinical trials, particularly the Phase 2b trial for the vitiligo treatment VYN201. The vitiligo trial, which has completed enrollment, will assess the safety and efficacy of a topical gel over 24 weeks with results expected in mid-2025. H.C. Wainwright’s optimism is based on positive outcomes from earlier trials, reinforcing their price target of $5.75 for VYNE. These developments reflect the company’s ongoing efforts to address unmet needs in chronic inflammatory and immune-mediated conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.